On April 13, 2022 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of preclinical data on the company’s anti-CD27 agonist lead antibodies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Kineta, APR 13, 2022, View Source;utm_medium=rss&utm_campaign=kineta-unveils-new-preclinical-data-on-its-anti-cd27-agonist-lead-antibodies-at-aacr-2022 [SID1234612134]). Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, presented the company’s poster unveiling new preclinical data. Kineta is developing fully human anti-CD27 agonist antibodies for the treatment of blood cancers and solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Kineta’s anti-CD27 program was developed through our innate immunity expertise and the company’s proprietary PiiONEER platform. We have confirmed very exciting data with our lead anti-CD27 antibodies demonstrating their activity in inducing T cells as well as NK cell activation" said Dr. Guillaudeux. "We are encouraged with these preclinical data and believe that CD27 is an important immuno-oncology target for treating cancer patients with its capability of influencing both the innate and adaptive antitumor immune response ."
Key results from the AACR (Free AACR Whitepaper) poster presentation:
Evaluated 3 lead therapeutic antibodies from our library of 147 fully human anti-CD27 monoclonal antibodies generated in Trianni mice.
Confirmed lead antibodies’ binding potency and cross-reactivity with non-human primate CD27 but not with the murine CD27.
Lead candidates demonstrate strong agonist proprieties. They induce NK cell activation as well as T cell proliferation and activation after engagement of NFκ
Lead antibodies will be evaluated as a single agent or in combination with other immuno-therapies in vivo in solid and hematological mouse tumor models in hCD27-KI mice.
Click on the link below to access the poster
CD27 Publications – Poster Presentation at ESMO (Free ESMO Whitepaper) 2022
Presentation Details
Title: CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number: 5588
Presenter: Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title: Therapeutic Antibodies 3
Session Time: April 13, 2022 9:00AM – 12:30PM Central Time
Location: Poster Section 39
Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.